CORE--Clinical Core
CORE--临床核心
基本信息
- 批准号:6900242
- 负责人:
- 金额:$ 32.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-05-20 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Aims of our Clinical Core are to provide access to a large group of patients with sickle cell disease who will be potentially available for collaborative inter-center clinical trials and for the studies of investigators within the Boston Comprehensive Sickle Cell Center. We will also deliver the highest level of patient care available by assuring access to physicians and nurses specially trained in managing hemoglobinopathies who are aware of the most recent advances in sickle cell disease treatment. Three medical centers in Boston, Boston Medical Center, Brigham and Women's Hospital and Children's Hospital, and, the University of Mississippi Medical Center provide access to more than 1600 patients with sickle cell disease. Each component of the Clinical Core is staffed by one or more physicians experienced in the care of patients with sickle cell disease and by a similarly experienced nursing staff. Each clinic has a long and successful record of participation in clinical trials in sickle cell disease.
我们的临床核心的目的是提供访问一个大组的镰状细胞病患者谁将有可能用于协作中心间的临床试验和研究人员在波士顿综合镰状细胞中心的研究。我们还将通过确保获得经过血红蛋白病管理专门培训且了解镰状细胞病治疗最新进展的医生和护士,提供最高水平的患者护理。波士顿的三个医疗中心,波士顿医疗中心,布里格姆妇女医院和儿童医院,以及密西西比大学医疗中心,为1600多名镰状细胞病患者提供服务。临床核心的每个组成部分都配备了一名或多名在镰状细胞病患者护理方面经验丰富的医生以及经验丰富的护理人员。每个诊所都有参与镰状细胞病临床试验的长期成功记录。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin H. Steinberg其他文献
Hemoglobin Terre Haute arginine beta 106. A posthumous correction to the original structure of hemoglobin Indianapolis.
血红蛋白 Terre Haute 精氨酸 beta 106。对印第安纳波利斯血红蛋白原始结构的死后修正。
- DOI:
10.1016/s0021-9258(19)67667-2 - 发表时间:
1991 - 期刊:
- 影响因子:4.8
- 作者:
M. Coleman;Martin H. Steinberg;J. Adams - 通讯作者:
J. Adams
Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients
Hb S 杂合性和新型 LCR 缺失引起的镰状细胞病:两名患者的报告
- DOI:
10.1002/ajh.21480 - 发表时间:
2009 - 期刊:
- 影响因子:12.8
- 作者:
S. Koenig;Esmira Becirevic;Miriam S.C. Hellberg;M. Y. Li;Jason C.C. So;J. Hankins;Russell E. Ware;Lillian C McMahon;Martin H. Steinberg;Hong‐yuan Luo;D. H. Chui - 通讯作者:
D. H. Chui
Modulation of the phenotypic diversity of sickle cell anemia.
镰状细胞贫血表型多样性的调节。
- DOI:
10.3109/03630269609027906 - 发表时间:
1996 - 期刊:
- 影响因子:1
- 作者:
Martin H. Steinberg - 通讯作者:
Martin H. Steinberg
A New Gene Deletion in the α-Like Globin Gene Cluster as the Molecular Basis for the Rare α-Thalassemia-1 {–/αα<em>)</em> in Blacks: HbH Disease in Sickle Cell Trait
- DOI:
10.1182/blood.v67.2.469.469 - 发表时间:
1986-02-01 - 期刊:
- 影响因子:
- 作者:
Martin H. Steinberg;Mary B. Coleman;Junius G. Adams III;Robert C. Hartmann;Hussein Saba;Nicholas P. Anagnou - 通讯作者:
Nicholas P. Anagnou
High Hemoglobin A<sub>2</sub> β<sup>0</sup>-Thalassemia Due to a 532-Basepair Deletion of the 5' β-Globin Gene Region
- DOI:
10.1182/blood.v77.5.1100.1100 - 发表时间:
1991-03-01 - 期刊:
- 影响因子:
- 作者:
John S. Waye;Shi-Ping Cai;Barry Eng;Cathy Clark;Junius G. Adams;David H.K. Chui;Martin H. Steinberg - 通讯作者:
Martin H. Steinberg
Martin H. Steinberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin H. Steinberg', 18)}}的其他基金
Genome-Wide Association Studies in Sickle Cell Anemia and in Centenarians
镰状细胞性贫血和百岁老人的全基因组关联研究
- 批准号:
7626008 - 财政年份:2007
- 资助金额:
$ 32.94万 - 项目类别:
Genome-Wide Association Studies in Sickle Cell Anemia and in Centenarians
镰状细胞性贫血和百岁老人的全基因组关联研究
- 批准号:
7226507 - 财政年份:2007
- 资助金额:
$ 32.94万 - 项目类别:
Genome-Wide Association Studies in Sickle Cell Anemia and in Centenarians
镰状细胞性贫血和百岁老人的全基因组关联研究
- 批准号:
7430271 - 财政年份:2007
- 资助金额:
$ 32.94万 - 项目类别:
相似海外基金
From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
- 批准号:
MR/Y013050/1 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
- 批准号:
495575 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
- 批准号:
2884930 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
- 批准号:
10855627 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10895949 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
- 批准号:
10891325 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 32.94万 - 项目类别: